Next Article in Journal
Targeting T Cell Activation in Immuno-Oncology
Previous Article in Journal
Immuno-Oncology—The New Paradigm of Lung Cancer Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue s2
10.3747/co.27.5223
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

by
K. Esfahani
1,
L. Roudaia
1,
N. Buhlaiga
1,
S.V. Del Rincon
2,
N. Papneja
1 and
W.H. Miller
1,*
1
Departments of Medicine and Oncology, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Rossy Cancer Network, McGill University, Montreal, QC, Canada
2
Department of Oncology, Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s2), 87-97; https://doi.org/10.3747/co.27.5223
Submission received: 7 January 2020 / Revised: 4 February 2020 / Accepted: 9 March 2020 / Published: 1 April 2020

Abstract

Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Immunotherapy has now firmly established itself as a novel pillar of cancer care, from the metastatic stage to the adjuvant and neoadjuvant settings in numerous cancer types. In this review article, we highlight how the history of cancer immunotherapy paved the way for discoveries that are now part of the standard of care. We also highlight the current pitfalls and limitations of cancer checkpoint immunotherapy and how novel research in the fields of personalized cancer vaccines, autoimmunity, the microbiome, the tumour microenvironment, and metabolomics is aiming to solve those challenges.
Keywords: immune checkpoint inhibitors; personalized cancer vaccines; immune-related adverse events; microbiome studies; metabolomics immune checkpoint inhibitors; personalized cancer vaccines; immune-related adverse events; microbiome studies; metabolomics

Share and Cite

MDPI and ACS Style

Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.V.; Papneja, N.; Miller, W.H. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Curr. Oncol. 2020, 27, 87-97. https://doi.org/10.3747/co.27.5223

AMA Style

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Current Oncology. 2020; 27(s2):87-97. https://doi.org/10.3747/co.27.5223

Chicago/Turabian Style

Esfahani, K., L. Roudaia, N. Buhlaiga, S.V. Del Rincon, N. Papneja, and W.H. Miller. 2020. "A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future" Current Oncology 27, no. s2: 87-97. https://doi.org/10.3747/co.27.5223

APA Style

Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020). A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Current Oncology, 27(s2), 87-97. https://doi.org/10.3747/co.27.5223

Article Metrics

Back to TopTop